Form 4: Impact Biomedical CEO Acquires 500 Shares in Open Market Transaction

Impact Biomedical's CEO, Frank D. Heuszel, purchased 500 shares of common stock at a price of $2.2578 per share.

Summary

• Frank D. Heuszel, the Chief Executive Officer of Impact Biomedical Inc., acquired 500 shares of the company's common stock on December 5, 2024.
• The shares were purchased at a price of $2.2578 per share.
• Following this transaction, Mr. Heuszel directly owns 97,344 shares of Impact Biomedical stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive sign, but the transaction is small and doesn't indicate a major shift in the company's outlook.

Positives

• The CEO's purchase of shares may indicate confidence in the company's future prospects.

Industry Context

This is a routine disclosure of an insider transaction, which is common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Insider trading disclosures are a standard practice for publicly listed companies, ensuring transparency and compliance with securities regulations.
• The transaction is relatively small in volume, suggesting it is not a major market-moving event compared to large institutional trades or block trades.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the CEO's purchase.

Key Dates

Keywords

Impact Biomedical, Frank D. Heuszel, stock purchase, insider trading, common stock, CEO, share acquisition